Session » Cytokines & Cell Trafficking Poster

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 6

A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 4

AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine

9:00AM-11:00AM: Abstract Number: 2

Baseline Cytotoxic Gene Expression Associates with Ustekinumab Response in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 11

Biomarker Changes for Patients with Rheumatoid Arthritis Receiving Tofacitinib with Methotrexate or Glucocorticoids vs Tofacitinib Monotherapy

9:00AM-11:00AM: Abstract Number: 9

Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 7

Citrullination of Interleukin 6 Augments Its Pro-inflammatory Capacity and Signaling Potency Through Interleukin-6 Receptor in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 8

CKD-506, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, Regulates Inflammatory Responses Through NF-kB and AP-1 Signaling

9:00AM-11:00AM: Abstract Number: 20

Comparative Efficacy of Beta-2-Glycoprotein I Domain V Structural Analogue Variants in Preventing Antiphospholipid Antibody-Mediated Endothelial Cell Activation

9:00AM-11:00AM: Abstract Number: 15

CYR61/TGF-β Axis Promotes Adventitial Fibrosis of Takayasu Arteritis in the IL-17 Mediated Inflammatory Microenvironment

9:00AM-11:00AM: Abstract Number: 19

Inhibition of IkB Kinase-IKK Complex of Canonical NF-κB Pathway in Antiphospholipid Antibody-Mediated Endothelial Cell Activation

9:00AM-11:00AM: Abstract Number: 5

Interferon Kappa Promotes the Development of Psoriasis

9:00AM-11:00AM: Abstract Number: 1

Interleukin-6 Promotes Osteoclast-like Phenotype in Human Rheumatoid Arthritis Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 12

Intraarticular and Circulatory Cytokine Responses to Chlamydia Trachomatis: A Clinical Study in Reactive Arthritis/ Undifferentiated Spondyloarthropathy Patients

9:00AM-11:00AM: Abstract Number: 16

Monoclonal ACPA Promote Synovial Fibroblasts Migration Through a Peptidylarginine Deiminases (PAD) Dependent Pathway

9:00AM-11:00AM: Abstract Number: 3

Pannexin-1 KO Mice Are Unresponsive to Tenofovir Induced Bone Loss

9:00AM-11:00AM: Abstract Number: 10

Roles of Histone Acetyltransferases CBP/p300 and Transcriptional Factor RORα/REV-ERBα Against TNFα-induced CCL2 Expression in RA-FLSs

9:00AM-11:00AM: Abstract Number: 14

Sec16A Abnormalities Affect the Intracellular Trafficking of HLA-B27 in the Pathogenesis of Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 13

The Effect of Estrogen and Interferon γ on the Immunobiology of Minor Salivary Gland Mesenchymal Stromal Cells

9:00AM-11:00AM: Abstract Number: 17

Transcription Factor Fli-1 Impacts Lupus Nephritis by Orchestrating CXCL10/CXCR3 Axis

9:00AM-11:00AM: Abstract Number: 18

Undifferentiated Connective Tissue Disease at Risk for SSc: Potential Role of Circulating CXCL-10, CXCL-11 and IL-33 in Predicting Disease Evolution

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].